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Extracellular matrix (ECM) remodeling is essential for facilitating developmental processes. ECM remodeling, accomplished by
matrix metalloproteinases (MMPs), is regulated by endogenous tissue inhibitors of metalloproteinases (TIMPs). While the TIMP
N-terminal domain is involved in inhibition of MMP activity, the C-terminal domain exhibits cell-signaling activity, which is TIMP
and cell type dependent. We have previously examined the distinct roles of the Xenopus laevis TIMP-2 and -3 C-terminal domains
during development and here examined the unique roles of TIMP-1 N- and C-terminal domains in early X. laevis embryos. mRNA
microinjection was used to overexpress full-length TIMP-1 or its individual N- or C-terminal domains in embryos. Full-length and
C-terminal TIMP-1 resulted in increased lethality compared to N-terminal TIMP-1. Overexpression of C-terminal TIMP-1 resulted
in significant decreases in mRNA levels of proteolytic genes including TIMP-2, RECK, MMP-2, and MMP-9, corresponding to
decreases in MMP-2 and -9 protein levels, as well as decreased MMP-2 and MMP-9 activities. These trends were not observed with
the N-terminus. Our research suggests that the individual domains of TIMP-1 are capable of playing distinct roles in regulating the
ECM proteolytic network during development and that the unique functions of these domains are moderated in the endogenous
full-length TIMP-1 molecule.

1. Introduction
Remodeling of the extracellular matrix (ECM) is a dynamic
process that is necessary for normal development [1]. Matrix
metalloproteinases (MMPs) are a large family of 24 Zn2+ dependent endopeptidases that cleave various components of
the ECM leading to changes in cell signaling and cell movement that are required during development [2]. Controlled
inhibition of MMP activity is needed to prevent excessive
ECM degradation and is largely carried out by the tissue
inhibitors of metalloproteinases (TIMPs), as well as the cell
surface MMP inhibitor REversion-inducing Cysteine-rich
protein with Kazal motifs (RECK) [3]. Maintaining proper
balance between MMP activity and inhibition is important
during embryogenesis and facilitates many developmental
events including organogenesis and angiogenesis [4, 5], and
disrupting this balance can have deleterious effects [6, 7].
Inhibition of MMP-2 or -9, two potent ECM proteases,

can lead to axial defects and incomplete neural crest cell
migration, respectively [7, 8]. Knockout of membrane-bound
MMP-14 (MT1-MMP) during mouse development is embryonic lethal [8–10], as is knockout of RECK due to defects in
angiogenesis [11]. Additionally, our lab has shown that overexpression of TIMP-2 and -3 during Xenopus laevis development leads to axial and neural tube defects [12]. Thus, disruption of activity levels in this proteolytic ECM remodeling
network is detrimental during development.
TIMPs constitute a family of only 4 secreted proteins
(TIMP 1–4), which bind MMPs in a 1 : 1 manner to inhibit
their proteolytic activity [13]. The four mammalian TIMPs
share similar domain structure and 40% amino acid sequence
similarity, including 12 conserved cysteine residues which
result in the formation of 6 disulfide bonds [14]. TIMPs
consist of structurally and functionally distinct N- and Cterminal domains, each of which is stabilized by 3 disulfide
bonds [14]. The N- and C-terminal domains boundary is
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found between cysteine 6 and 7, in between which there are
only one or two amino acids. The N-terminal domains of all
TIMPs function to inhibit MMP activity by binding to the
zinc-active site found in the catalytic domain of all MMPs
[15]. The N-terminal domain of a TIMP is both necessary and
sufficient for MMP inhibition [15]. In contrast, the smaller
C-terminal domain of TIMPs may influence cell behavior in
an MMP-independent manner through direct regulation of
a number of cell-signaling pathways [16]. Characterization
of cell surface binding partners and specific signaling events
involving TIMP C-terminal domains has been carried out in
vitro, and activation of a resultant signaling pathway seems to
vary with the specific TIMP expressed as well as the cell type
it is expressed in [17].
Of the four mammalian TIMPs, TIMP-1, -2, and -4 all
function pericellularly, while TIMP-3 can be sequestered
away from the cell surface in the ECM [18, 19]. TIMP1 was first identified for its erythroid potentiating activity
and as an inhibitor of metalloproteinases [20, 21]. Both
the N- and C-terminal domains of TIMP-1 have now been
well characterized in vitro. Interestingly, the two domains
of TIMP-1, as well as of the other TIMPs, have the ability
to fold and function autonomously in vitro [15, 22]. TIMP-1
can inhibit MMP-2 and -9 activity, which are two powerful
ECM proteases that cleave abundant ECM components [3,
23]. Additionally, TIMP-1, through its C-terminal domain,
has been linked to regulation of specific cell-signaling pathways. TIMP-1 has been shown to promote cell proliferation,
although the receptor-mediated events involved in this pathway remain unidentified [24]. More recently, TIMP-1 has
been associated with inhibition of apoptosis in several human
cell lines [25, 26]. TIMP-1 may also increase the abundance of
cellular survival and differentiation factors, and this activity
has been linked to association of TIMP-1 with cell surface
CD63 and 𝛽1 integrin [25, 27–29]. To date, however, the
specific activities of the individual TIMP-1 domains have
not been well characterized in vivo, and the specific roles
of the two domains as they pertain to development remain
unknown.
Our lab has previously preformed a series of domain specific overexpression experiments, which suggest that TIMP-2
and -3 N- and C-terminal domains may have specific MMPdependent and independent functions, respectively, during
embryogenesis in X. laevis [12]. In the present study, we use a
similar approach to characterize the unique functions of the
TIMP-1 N- and C-terminal domains during early X. laevis
development. Here we show that the TIMP-1 C-terminal
domain can act autonomously to alter gene expression and
MMP levels in X. laevis embryos, and that axial and head
defects resulting from C-terminal domain overexpression are
different than those observed with the N-terminal domain.

2. Materials and Methods
2.1. Cloning of X. laevis TIMP-1. X. laevis TIMP-1 was cloned
using primers designed from unannotated X. laevis clone
AAI41767.1. Primers used were forward: 5 ACAGAAGGACTGCCCAGCC and reverse: 5 CAAAACACTTCTCCTTCGAG. Xenopus TIMP-1 was cloned from total cDNA from
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stage 35 embryos using SuperScript Reverse Transcriptase
(Life Technologies) with Platinum Taq DNA Polymerase
High Fidelity (Life Technologies). The full-length TIMP-1
amplicon was cloned into the pCR II-TOPO vector (Life
Technologies), and the sequence of full-length X. laevis
TIMP-1 was confirmed at the Robarts Research Institute DNA
Sequencing Facility, at the University of Western Ontario, and
submitted to Genbank as KF018236.
2.2. Comparison of Amino Acid Identity between Vertebrate
TIMP-1 N- and C-Terminal Domains. Sequence alignments
and amino acid identities were compared using all annotated full-length TIMP-1 sequences known at the time of
publication. Accession numbers were as follows: human
(Homo sapiens) NP 003245.1; mouse (Mus musculus)
AAH51260.1; rat (Rattus norvegicus) EDL97726.1; cow (Bos
Taurus) AAP44413.1; horse (Equus Caballus) NP
001075984.1; rabbit (Oryctolagus cuniculus) AAW79053.1;
shark (Callorhinchus milii) AFK11387.1; newt (Notophthalmus
viridescens) ABB88702.1.
2.3. Animals and Ethics Statement. Adult X. laevis were
purchased from Ward’s Natural Science (Rochester, NY).
Fertilization and rearing of embryos were done in accordance with standard protocols [30] and staged according to
Nieuwkoop and Faber [31]. Animals were housed and treated
in accordance with UWO and CCAC guidelines. The protocol
was approved by University of Western Ontario Animal Use
Subcommittee/University Counsel on Animal Care, AUP
number 2009-44.
2.4. Generation of TIMP-1 mRNA Constructs for Microinjection. PCR was used to generate full-length, N-terminal, or
C-terminal TIMP-1 (hemagglutinin) HA-tagged constructs
using the full-length clone as a template. Briefly, all TIMP-1
mRNA constructs (T1FL, T1N, and T1C) were HA tagged on
their most C-terminal end. The C-terminal domain construct
(T1C) was engineered to include its appropriate secretory
signal sequence through a two-step PCR process. Forward
and reverse primers used were as follows:
T1FL 5 AGATCTATGTTGTACCTTGTGGTTGTG;
5 CAGTCTGCTGCCACAACACAATACCCATACGATGTTCCAGATTACGCTACTAGT;
T1N 5 AGATCTATGTTGTACCTTGTGGTTGTG;
5 GTGTATCGCAAAGCCTGTTCCTACCCATACGATGTTCCAGATTACGCTACTAGT;
T1C signal sequence 5 AGATCTATGTTGTACCTTGTGGTTGTG;
T1C signal sequence link 5 CTCAGCCAGGAGGTGTTGGGGTGCAACATCGTCCCCTGCTAT;
T1C-terminal domain link 5 TGCAACATCGTCCCCTGCTAT;
5 CAGTCTGCTGCCACAACACAATACCCATACGATGTTCCAGATTACGCTACTAGT.
Following PCR amplification, the sequences of all amplicons
were verified. All TIMP-1 constructs were subsequently ligated into the EcoRV/SpeI restriction sites of the T7TS plasmid.
mMessage mMachine was used with T7 RNA polymerase
(Ambion) to synthesize stable capped, poly(A)-tailed mRNA
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transcripts that were dissolved in filtered water. RNA was
quantified using NanoVue spectrophotometer (GE), and its
integrity was assessed using 1% agarose gel electrophoresis.
GFP mRNA was generated and quantified in a similar way
from a proven T7TS-GFP construct plasmid [32]. The T7TS
plasmid and HAs tag have previously been used extensively
by our lab and others and their utilities have been demonstrated.
2.5. mRNA Microinjection. Prior to injection, X. laevis
embryos at the one-cell stage were transferred from 0.1X
(Marc’s Modified Ringer’s solution) MMR into 1X MMR
containing 4% Ficoll. Embryos were injected at the onecell stage with TIMP-1 full-length, N-terminal, or C-terminal
(T1FL, T1N, and T1C) constructs, or GFP mRNA, using 10 𝜇m
diameter glass needles. Embryos were injected with 4 ng of
mRNA in a volume of 2.3 nL. Embryos were maintained in
1X MMR containing 4% Ficoll for 5 hours following injection
and then transferred to 0.1 X MMR solution for rearing.
Embryos that were dead or abnormal 2 hours after injection
were removed, and the remaining embryos (representing
the 100% being monitored) were observed for phenotypic
abnormalities. The percent of normal embryos (no visible
defects) was quantified for two days following injection (until
stage 30 in development). Mean values were obtained from
three independent sets of experiments.
2.6. Semiquantitative RT-PCR Analysis. Semiquantitative
RT-PCR analysis was used to examine changes in proteolytic
gene expression patterns or to confirm upregulation of TIMP1 expression following injection with T1FL, T1N, or T1C
constructs compared to control embryos. Total RNA was
extracted from 10 injected and control embryos using RNeasy
Mini Kit (Qiagen) and 1 𝜇g RNA was reversely transcribed
using qScript cDNA Supermix (Quanta Bioscienes). PCR was
carried out using KAPA Taq PCR Kit (KAPA Biosystems) and
the Eppendorf Thermal Cycler. The cycling conditions were
as follows: initial denaturation, 95∘ C for 2 min, followed by
28 cycles of the following: denature 95∘ C 30 sec, anneal 55∘ C
30 sec, and extend 72∘ C 30 sec. Primers, based on the X. laevis
sequences, were as follows:
Ef1𝛼 5 TGTTGGCAGAGTGGAGACTG and 5 GGCCAAGTGGAGGATAGTCA;
TIMP-2 5 AGGTAAAGCCGATGGTGATG and 5 GCCTGTCGTCCGTTTATGTT;
TIMP-3 5 TTCCAAGAACGAGTGCCTCT and 5 GGGATCCGTGGTGTTTATTG;
RECK 5 GGATGTTTACAGGTCTACCC and 5 GGCTCTGTTCCTCCAAAGAT;
MT1-MMP 5 CTATGAGGCGATTCGGAGAG and

5 GCCACCAGGAACAGATCATT; MMP-2 5 TGATTCTGGTCGCTCAGATG and 5 CTTGTTTCCCAGGAAGGTGA;
MMP-9 5 AGGACCATGGGGATCCTTAC and 5 AACACAAGGCTGCCCATTAC;
T1FL and T1C 5 ATGTTGTACCTTGTGGTTGT and

5 TTATTGTGCTGTGCAGCAG;
T1N 5 ATGTTGTACCTTGTGGTTGT and 5 GGAACAGGCTTTGCGATACAC.
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2.7. Protein Preparations and Western Blotting. Stage 30
embryos injected with T1FL, T1N, or T1C mRNA constructs,
or uninjected controls, were subject to protein extraction.
Briefly, 10 embryos were lysed and sonicated in 100 𝜇L
modified RIPA buffer (150 mM NaCl, 50 mM tris (pH 8.0),
1.0% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 10 𝜇L/mL
Halt Protease Inhibitor Cocktail (Thermo Scientific), and
10 𝜇L/mL Halt Phosphatase Inhibitor Cocktail (Thermo Scientific)) and lysates were centrifuged at 15,000 g for 25 min
at 4∘ C. The supernatant was removed and protein was
quantified using BCA protein assay kit (Thermo Scientific)
according to manufacturer’s instructions. 25 𝜇g of protein was
electrophoresed on a 10% SDS gel and transferred to PVDF
membrane (Bio-Rad). Membranes were washed three times
with TBST (Tris-buffered saline containing 0.5% Tween20), blocked in 5% skim milk in TBST for 40 min at room
temperature, and incubated overnight at 4∘ C with primary
rabbit anti-HA antibody (1 : 1000 dilution; Santa Cruz) or
mouse anti-𝛽-actin antibody (1 : 1000 dilution; Santa Cruz).
Membranes were washed 3 times in TBST and incubated with
secondary antibodies goat anti-rabbit HRP (1 : 5000 dilution;
Life Technologies) or goat anti-mouse HRP (1 : 5000 dilution;
Bio-Rad), respectively, for 1 hour at room temperature.
Membranes were washed 3 times in TBST and HRP activity
was detected and visualized using SuperSignal West Pico
Chemiluminescent Substrate (Thermo Scientific) and BioRad Quantity One 4.4.0 software.
2.8. Zymography and Reverse Zymography. 12.5 𝜇g of protein
(as extracted for Western blotting) from T1FL, T1N, or T1C
injected embryos, or uninjected control embryos, was diluted
1 : 1 with 2X SDS-loading buffer (0.5 M Tris-HCl, pH 6.8, 10%
SDS, 2.5% glycerol, and 1% Bromophenol Blue). For zymography, protein samples were electrophoresed on a 1% gelatin and
10% polyacrylamide gel. For reverse zymography, protein was
electrophoresed on a 1% gelatin and 15% polyacrylamide gel
copolymerized with MMP-conditioned media from Hs578t
cells according to [33]. Hs578t cells were chosen for their
ability to secrete high levels of MMPs, particularly MMP2 and -9. For both zymography and reverse zymography,
gels were electrophoresed in 1X zymogram running buffer
(25 mM Tris, 192 mM glycine, and 0.1% SDS), followed by ingel renaturation for 30 min at room temperature in renaturing
solution (2.5%Triton X-100). Substrate cleavage was carried
out by incubating gels in zymogram developing buffer (pH
7.5, 50 mM Tris, 200 mM NaCl, 5 mM CaCl2 (anhydrous),
and 0.02% Brij-35) for 48 hours at 37∘ C. For zymography,
MMP activity was visualized as clear bands against a dark
background after staining with 0.5% Coomassie blue (BioRad). For reverse zymography, TIMP activity was visualized
as dark bands against light background after staining with
0.5% Coomassie blue (Bio-Rad). Gels were visualized and
photographed using Bio-Rad Quantity One 4.4.0 software.
2.9. Statistical Analysis. All statistical analysis was performed
using the IBM SPSS Statistic 19 program. Results were
presented as mean ± standard error. Statistical significance
was determined using one-way ANOVA variance analysis
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Figure 1: Evolutionary conservation of TIMP-1 N- and C-terminal domains. Sequence analysis comparing amino acid sequence identity of X.
laevis TIMP-1 N- and C-terminal domains versus known (at the time of publication) vertebrate species. Light purple boxes represent species
whose N-terminal domains were more highly conserved with X. laevis TIMP-1 than their C-terminal domains. Light pink boxes represent
species whose C-terminal domains were more highly conserved with X. laevis TIMP-1 than their N-terminal domains. Blue boxes represent
species with equal conservation with both X. laevis TIMP-1 N- and C-terminal domains.
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Figure 2: Confirmation of full-length, N-terminal, or C-terminal TIMP-1 constructs overexpressed in X. laevis embryos. 4 ng of mRNA
coding for full-length (T1FL), N-terminal (T1N), or C-terminal (T1C) TIMP-1 constructs was microinjected into X. laevis embryos at the 1cell stage. (a) Overexpression of TIMP-1 mRNA as shown by RT-PCR analysis. RNA was isolated from stage 15 embryos. Control (uninjected)
embryos expressed TIMP-1 at very low levels. Primers specific to each construct were used to confirm mRNA levels of T1FL (678 bp), T1N
(453 bp), and T1C (252 bp). RT-PCR of EF1𝛼 was used as a loading control. (b) Increased levels of TIMP-1 constructs as shown by Western
blot analysis. All constructs are HA tagged. Protein was isolated from stage 30 embryos. Anti-HA antibodies were used to confirm expression
of each construct at the protein level (T1FL = 26 KDa, T1N = 18 KDa, and T1C = 12 KDa). No HA was detected in control uninjected embryos.
𝛽-actin was used as protein loading control.

and Dunnett’s post hoc test. Differences were considered
statistically significant when 𝑃 < 0.05.

3. Results
3.1. Amino Acid Sequence Conservation of Vertebrate TIMP-1
N- and C-Terminal Domains. A direct amino acid sequence
comparison of the individual TIMP-1 N- and C-terminal
domains between species has not previously been reported.
Current TIMP-1 protein sequences were identified, which
thus far have only been confirmed in vertebrates. To investigate whether the unique functions of these domains may
be concurrent with their patterns of evolutionary conservation, we cloned X. laevis TIMP-1 (GenBank: KF018236)
and compared its N- and C-terminal domains with currently
known mammalian and nonmammalian TIMP-1 sequences.
The N-terminal domain of X. laevis TIMP-1 was more
highly conserved than its C-terminal domain with 7 of 9
vertebrate species analyzed (Figure 1). In general, the Nterminal domains of all species were more highly conserved
than the C-terminal domains, with the exception of horse

and cow, where the C-terminal domains were more highly
conserved between species (Figure 1).
3.2. TIMP-1 RNA and Protein Were Upregulated in X. laevis Embryos following Ectopic Expression of TIMP-1 mRNA
Constructs. In order to characterize the unique roles of
TIMP-1 N- and C-terminal domains during development, we
have performed a series of domain specific overexpression
experiments. For this purpose, we generated full-length, Nterminal, and C-terminal HA-tagged TIMP-1 mRNA constructs (T1FL, T1N, and T1C, resp.), which were injected
into newly fertilized X. laevis embryos (1-cell stage). Total
RNA was collected from injected and control embryos 1
day after fertilization (stage 15), and RT-PCR analysis was
used to verify levels of TIMP-1 mRNA transcripts in injected
embryos compared to controls (Figure 2(a)). Uninjected
control embryos contained much lower levels of TIMP-1
mRNA compared to T1FL, T1N, or T1C injected embryos,
which showed relatively equal but elevated levels of TIMP1 mRNA, relative to Ef1𝛼 (loading control; Figure 2(a)). By
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Figure 3: Phenotypic effects of overexpression of full-length, Nterminal, or C-terminal TIMP-1 constructs. Following injection,
photographs were taken of representative embryos at stage 30.
(a) Control (uninjected) embryos were phenotypically normal.
Microinjection of T1FL (b) and T1N (c) constructs both resulted
in normal anterior (head) development but truncated posterior
axes. (d) Microinjection of T1C constructs resulted in lack of head
structures, other head defects, and neural tube closure failure. Panel
(a) magnification is lower than in (b), (c), and (d). Embryos are 1 mm
in diameter.

two days after fertilization (stage 30), each HA-tagged TIMP1 construct was still present and detectable on Western blot
via HA antibody in injected embryos (Figure 2(b)), indicating
that all constructs produced stable protein products.
3.3. Overexpression of Full-Length, N-Terminal, and C-Terminal TIMP-1 Constructs Produced Unique Developmental
Phenotypes. Following injection of each TIMP-1 construct,
embryos were monitored for gross morphological changes
in development for 2 days after fertilization (until developmental stage 30). Uninjected control embryos were morphologically normal (Figure 3(a)). By stage 30 in development, embryos overexpressing full-length (T1FL) or Nterminal (T1N) TIMP-1 displayed relatively normal anterior
(head) development with posterior axis defects. T1FL and
T1N injected embryos had a bent axis phenotype along
with truncated anterior/posterior axes compared to controls
(Figures 3(b) and 3(c), resp.). Embryos overexpressing Cterminal TIMP-1 (T1C) also resulted in truncated axis defects
compared to controls, as well as other developmental abnormalities: chiefly, lack of head structures, other head defects,
and failure of the neural tube to close (Figure 3(d)). More
specifically, overexpression of T1C resulted in more severe
phenotypic consequences than overexpression of T1FL or
T1N constructs.
3.4. Overexpression of Full-Length and C-Terminal TIMP-1
Resulted in Increased Embryonic Lethality Compared to Overexpression of N-Terminal TIMP-1. To compare and measure
the effects of overexpressing full-length versus N-terminal
or C-terminal TIMP-1 during X. laevis development, T1FL,
T1N, and T1C injected embryos were monitored for 48 hours
following fertilization, and the percent of normal embryos
(embryos that were alive and morphologically normal) was

10
0

1

15
Developmental stage

Control
T1FL
T1N

30

T1C
GFP

Figure 4: Overexpression of all three TIMP-1 constructs leads to
abnormal development and death. Following injection of mRNA
constructs at the 1-cell stage, embryos were scored for a normal
phenotype at stages 15 and 30. Dead and abnormal embryos were
counted as containing morphological defects. The graph illustrates
the percentage of normal embryos following injection of GFP
mRNA (GFP), or full-length (T1FL), N-terminal (T1N), or Cterminal (T1C) TIMP-1 mRNA constructs at the given stage. Control
embryos are uninjected. Results are based on 3 independent sets of
experiments; bars indicate standard error.

determined and quantified at stage 15 (1 day after fertilization)
and stage 30 (2 days after fertilization). More than 90%
of control embryos, or embryos injected with GFP (green
fluorescent protein) mRNA, developed normally during this
time period (Figure 4). Overexpression of all TIMP-1 constructs resulted in increased lethality compared to controls.
At stage 15, all constructs resulted in an approximate 20%
decrease in normal embryo numbers compared to controls
at the same stage (Figure 4). By stage 30, 66% of T1N
injected embryos developed normally, whereas T1FL and T1C
constructs were more detrimental with only 58% and 55%
normal development, respectively (Figure 4).
3.5. Overexpression of Full-Length, N-Terminal, or C-Terminal
TIMP-1 Constructs in X. laevis Embryos Altered Expression
of Proteolytic Genes. In order to examine the roles of fulllength, N-terminal, or C-terminal TIMP-1 in regulating ECM
remodeling in vivo, we investigated the expression patterns
of hallmark genes involved in regulating ECM proteolysis
following microinjection with T1FL, T1N, or T1C constructs
into X. laevis embryos. mRNA was collected from embryos
at stage 30 in development, as we had observed specific
and unique morphological defects at this time point with
overexpression of each construct (see Figure 3). Using semiquantitative RT-PCR, we assayed for changes in mRNA levels
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of the MMP inhibitors (TIMP-2, TIMP-3, and RECK), as well
as the MMPs (MMP-2, MMP-9, and MT1-MMP). All of these
genes have previously been shown to be important regulators
of ECM remodeling during development [8, 9, 12, 34]. mRNA
levels were normalized to Ef1𝛼 and compared to control
(uninjected) embryos.
Overexpression of T1C significantly decreased TIMP-2
mRNA relative to controls (Figure 5(a), 𝑃 < 0.05). T1FL and
T1N did not significantly alter TIMP-2 mRNA, although the
trend was toward the decrease for T1FL injected embryos.
Levels of TIMP-3 mRNA were not significantly altered
compared to control embryos following treatment with
any of our TIMP-1 constructs (Figure 5(b)). RECK expression was significantly decreased relative to controls following
injection of T1FL (𝑃 < 0.05) and T1C (𝑃 < 0.01, Figure 5(c)).
MMP-2 mRNA levels were significantly decreased compared to controls following overexpression of all constructs
(T1FL, T1N, and T1C; Figure 6(a), 𝑃 < 0.01). MMP-9
mRNA levels significantly decreased following injection of
T1C (Figure 6(b), 𝑃 < 0.05). No significant change in MMP9 mRNA levels was seen in embryos injected with T1FL or
T1N constructs (Figure 6(b)). Similarly, levels of MT1-MMP
mRNA were not altered relative to control embryos following
overexpression of any of our TIMP-1 constructs (Figure 6(c)).
3.6. Overexpression of TIMP-1 Constructs Decreased Amount
of Active MMP-2 and -9. To further understand how the individual TIMP-1 domains affect the proteolytic network in
vivo, gelatin zymography was used to measure changes in
the amounts of active MMP-2 and -9 in T1FL, T1N, or T1C
injected embryos relative to control (uninjected) embryos.
Embryos injected with T1FL, T1N, and T1C constructs
showed significantly decreased levels of active MMP-2 relative to control embryos (Figure 7(a), 𝑃 < 0.01). Injection with
T1FL and T1N constructs also resulted in decreased levels of
embryonic active MMP-9 relative to controls (Figure 7(b),
𝑃 < 0.05); however, interestingly, the T1C construct produced
the most significant decrease in MMP-9 activity (Figure 7(b),
𝑃 < 0.01).
3.7. Only Full-Length and N-Terminal TIMP-1 Domains
Directly Inhibited MMP Activity. In order to validate the
MMP-inhibitory activity of our full-length and N-terminal
TIMP-1 constructs and also to confirm that our C-terminal
TIMP-1 construct cannot directly inhibit MMPs, we performed reverse zymography. Reverse zymography is a modification of traditional zymography by incorporating gelatin
into the gel matrix as well as conditioned media from cancer
cells as a source of MMP-2 and -9 activity. Subsequently, the
proteins of interest are separated within the gel by molecular
weight. The gelatin is degraded by MMPs in the matrix,
except for where inhibited by active TIMPs. TIMP activity
is visualized as a dark band after staining with Coomassie
blue [33], representing a protected band corresponding to
the molecular weight of the active construct. Protein was
isolated from injected stage 30 embryos and analyzed for
MMP-inhibitory activity corresponding to T1FL, T1N, and
T1C construct sizes. T1FL and T1N constructs showed MMPinhibitory activity at the expected sizes of 26 KDa and
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18 KDa, respectively (Figure 8, white arrows), whereas the
T1C construct was not able to inhibit MMPs at the expected
size of 12 KDa (Figure 8, black arrow). Other bands represent
the presence of other unknown inhibitors.

4. Discussion
ECM remodeling is a key process involved in regulating tissue growth and morphogenesis during development.
Maintaining the appropriate balance between MMPs and
their inhibitors (TIMPs and RECK) is absolutely essential for
normal development, and disruption of this balance leads to
defects in neurulation, organogenesis, and angiogenesis [4,
5, 8]. Our understanding of the regulation of this proteolytic
network has become complicated by the discovery that TIMP
proteins have both MMP-inhibitory activity and MMPindependent cell-signaling activity [35]. With recent research
on TIMP C-terminal domains demonstrating their roles in
apoptosis, cell proliferation, and cell migration pathways, the
functions of the TIMP C-terminal domains are becoming
increasingly studied in vitro [24–26, 36]. At the present time
there is comparatively little research characterizing the roles
of the N- and C-terminal TIMP domains in vivo, particularly
as they pertain to development. Our lab has previously
examined the specific functions of the N- and C-terminal
domains of TIMP-2 and -3 during X. laevis development and
found that the two domains have unique functions when
overexpressed individually in X. laevis embryos [12]. To date,
there has been no comparison of the unique functions of
TIMP-1 N- and C-terminal domains in a developmental
context. Here we use mRNA overexpression to examine the
role of full-length TIMP-1 versus the roles of its individual
N-terminal and C-terminal domains during early X. laevis
development.
In order to examine whether distinct functions of the
two TIMP-1 domains are reflected in their evolutionary
conservation, we compared amino acid sequence identities
of the X. laevis TIMP-1 N- and C-terminal domains to other
known vertebrate TIMP-1 sequences. We found that the
TIMP-1 N-terminal domains were more highly conserved
than their C-terminal domains among most species analyzed,
with the exception of the large mammals, horse, and cow,
in which C-terminal domains were more highly conserved
(Figure 1). As the catalytic domains of MMPs are highly
conserved between species, it is not surprising that TIMP-1
N-terminal MMP-inhibitory domains are also well conserved
[37]. We have previously shown that the TIMP-2 N-terminal
domains are also more highly conserved across species than
their C-terminal domains, whereas, for TIMP-3, we found
that the C-terminal domains are more highly conserved
[12]. Our findings suggest that TIMP-1 may behave more
like TIMP-2 than TIMP-3 with respect to MMP inhibition.
Indeed, TIMP-3 is unique in that it is a good inhibitor of the
ADAM family of proteases [38]. Additionally, TIMP-3 binds
to ECM components through its C-terminal domain and is
sequestered away from the cell surface, whereas TIMP-1 and
-2 function in a pericellular manner [39].
In order to examine differences in the in vivo roles
of TIMP-1 N- and C-terminal domains, we generated and
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Figure 5: Effect of overexpression of full-length, N-terminal, or C-terminal TIMP-1 on mRNA levels of MMP inhibitors. Semiquantitative
RT-PCR analysis was used to measure changes in mRNA levels of (a) TIMP-2, (b) TIMP-3, and (c) RECK at stage 30, following microinjection
of 4 ng of TIMP-1 full-length (T1FL), N-terminal (T1N), or C-terminal (T1C) constructs into X. laevis embryos at the 1-cell stage. In each case
mRNA levels were measured relative to Ef1𝛼. The results are presented as mean ± standard error from 3 independent experiments. ∗ 𝑃 < 0.05
and ∗∗ 𝑃 < 0.01, all versus control (CONT; uninjected) embryos, as analyzed by one-way ANOVA and Dunnett’s post hoc test.
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Figure 6: Effect of overexpression of full-length, N-terminal, or C-terminal TIMP-1 on mRNA levels of MMPs. Semiquantitative RT-PCR
analysis was used to measure changes in mRNA levels of (a) MMP-2, (b) MMP-9, and (c) MT1-MMP at stage 30, following microinjection of
4 ng of TIMP-1 full-length (T1FL), N-terminal (T1N), or C-terminal (T1C) constructs into X. laevis embryos at the 1-cell stage. In each case
mRNA levels were measured relative to Ef1𝛼. The results are presented as mean ± standard error from 3 independent experiments. ∗ 𝑃 < 0.05
and ∗∗ 𝑃 < 0.01, all versus control (CONT; uninjected) embryos, as analyzed by one-way ANOVA and Dunnett’s post hoc test.
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Figure 7: Zymography demonstrated altered levels of active MMP-2 and MMP-9 following overexpression of TIMP-1 constructs. 4 ng of
mRNA coding for full-length (T1FL), N-terminal (T1N), or C-terminal (T1C) constructs was injected into X. laevis embryos at the 1-cell
stage and protein was isolated from stage 30 embryos. Gelatin zymography was used to measure changes in (a) MMP-2 and (b) MMP-9
activity. Zymogram (top) is representative of one experiment where the bright brand represents the active forms (63 and 84 kDa) of MMP2 and MMP-9, respectively. Graphs represent quantification of above zymogram, and data is presented as mean ± standard error from 3
independent experiments. ∗ 𝑃 < 0.05 and ∗∗ 𝑃 < 0.01, all versus control (CONT; uninjected) embryos, as analyzed by one-way ANOVA and
Dunnett’s post hoc test.
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Figure 8: Reverse zymography demonstrating full-length and Nterminal, but not C-terminal, TIMP-1 can directly inhibit MMP
activity. 4 ng of mRNA coding for full-length (T1FL), N-terminal
(T1N), or C-terminal (T1C) TIMP-1 constructs was injected into X.
laevis embryos at the 1-cell stage and protein was isolated from stage
30 embryos. MMP-inhibitory activity is represented by dark bands.
White arrows indicate the location of the expected inhibitory band
of the T1FL (26 KDa) and T1N (18 KDa) constructs, respectively.
Black arrow represents position of T1C (12 KDa) construct, which
cannot inhibit MMP activity as suggested by the light band.

overexpressed full-length, N- and C-terminal TIMP-1 mRNA
constructs in X. laevis embryos (T1FL, T1N, an T1C, resp.). We
found that treatment of embryos with T1C resulted in more
embryonic death and developmental defects than treatment
with T1FL or T1N (Figure 4). Consistent with this observation, overexpression of T1C also resulted in more severe
phenotypic defects in embryos by stage 30 in development,
with these embryos showing head and neural tube defects,
as well as truncated axes. In comparison, T1FL and T1N
injected embryos showed relatively normal head development but truncated anterior-posterior axes (Figure 3), indicating that the TIMP-1 C-terminal domain may contribute
to unique functions in development separate from the Nterminal domain.
In order to further investigate the roles of the two TIMP-1
domains, we performed RT-PCR analysis to examine changes
in mRNA levels of associated genes involved in the regulation
of ECM remodeling. We did not observe any change in
levels of TIMP-3 or MT1-MMP mRNA relative to control
embryos, following injection with full-length, N-terminal, or
C-terminal TIMP-1. This is consistent with previous work,

which showed that association of TIMP-1 with MT1-MMP
is exceptionally poor [40]. In contrast, TIMP-2 and RECK
mRNA levels decreased significantly compared to controls
following treatment of embryos with T1FL (𝑃 < 0.05) or T1C
(𝑃 < 0.01); however, these decreases were most pronounced
with T1C (Figure 5). This supports the concept that the Cterminal domain has the ability to regulate developmental
events independent of the N-terminal domain, presumably
through cell surface receptor-mediated signaling pathways.
Similarly, we found that overexpression of T1C resulted
in the most marked decreases in amounts of MMP-2 and -9
mRNA compared to control embryos, although, in the case
of MMP-2, ectopic expression of all three constructs significantly decreased MMP-2 mRNA (Figure 6). These results
were consistent with zymography, which showed that the
amounts of active MMP-2 and -9 proteins followed the same
trends as our RT-PCR analysis (Figure 7). Decreases in MMP2 and -9 protein and mRNA may be partially due to a regulatory feedback mechanism in the proteolytic network which
occurs from direct catalytic inhibition of MMPs by the Nterminal TIMP-1 domain, as T1N overexpression significantly
decreased MMP-2 mRNA and protein compared to control
embryos. Our results suggest, however, that the C-terminal
domain of TIMP-1 has the ability to regulate MMP mRNA
and protein levels independent of the N-terminal domain.
Reverse zymography using MMP-conditioned media from
Hs578t cells showed that TIC constructs cannot directly
inhibit MMP activity (Figure 8); yet overexpression of T1C
resulted in the most significant decreases in MMP-9 mRNA
and protein compared to control embryos (Figures 6(b) and
7(b)). Although the mechanism of action of the TIMP-1 Cterminal domain is still unknown, TIMP-1 has previously
been shown to bind to cell surface receptors on both
fibroblasts and MCF-7 breast cancer cells, which resulted in
translocation of TIMP-1 into the cell [40, 41]. Taken together
with the emerging discoveries of new cell surface binding
partners for TIMP-1 and its MMP-independent roles in cell
signaling [42], it is possible that the C-terminal domain of
TIMP-1 may function to regulate expression of proteolytic
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genes through a signaling mechanism separate from N-terminal MMP-inhibitory activity.

5. Conclusions
In summary, this research characterized in vivo the unique
role of the TIMP-1 C-terminal domain. In vitro studies have
demonstrated new roles for TIMP C-terminal domains in
cell signaling. Additionally, disease models have highlighted
the emerging significance of the C-terminal TIMP domains
in regulating the proteolytic network, as synthetic MMP
inhibitors designed to mimic TIMP N-terminal domains
failed as an anticancer therapy to block metastasis associated
with upregulated MMP activity [43]. Here we show for the
first time in vivo that the TIMP-1 C-terminal domain has
an independent role in regulating the proteolytic network
during development, at a time when this network is both
complex and highly regulated. We have no direct evidence
as to the mechanisms through which the individual ectopic
domains are manifesting developmental anomalies; however,
there is evidence that feedback is involved as disruption of the
precise embryonic proteolytic network was compensated for
by changes in the levels of key genes. Further, while there is
no evidence that nascent TIMP-1 is cleaved into its individual
domains, our research suggests that the functions of the
TIMP-1 N- and C-terminal domains depend on the affinities
of the individual domains for their binding partners, as well as
the stoichiometric levels of TIMP-1 relative to secreted MMPs
and cell surface receptors. Further in vivo studies are needed
to fully investigate whether there is preferential binding of
either domain in the context of abundant active MMPs and/or
cell surface receptors.
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